David M. Lee has been appointed vice president of quality at OsoBio. Mr. Lee is responsible for overseeing all quality-related functions to ensure continued compliance with cGMP, including quality systems, quality control and manufacturing quality assurance. Mr. Lee has more than 20 years of professional experience managing quality operations and API and sterile manufacturing.
Prior to joining the company, he served as director of validation and quality at Amgen, where he managed all validation activities for a $1.2-billion site expansion. He also managed production operations for two of the company’s flagship drugs, Neupogen and Neulasta.
“David’s knowledge and expertise in quality operations will support OsoBio’s ongoing ability to deliver exceptional sterile pharmaceutical manufacturing products and service,” said Milton Boyer, president of OsoBio. “David has already proven to be a great asset to the OsoBio team and the clients we serve.”